Po-0664 Mean Distance to Conformity as a Tool for Assessing Outlining in the Uk Scope 1 Oesophageal Chemoradiotherapy Trial

Gwynne, S.; Hurt, Chris; Spezi, Emiliano; Crosby, Tom; Staffurth, J.; Jena, R.

doi:10.1016/s0167-8140(12)70997-0

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Work has been conducted on the SCOPE 1 [20,40], SCALOP [41] and ARISTOTLE [42] trials. From this work, the advantages and disadvantages of the different CIs can be determined, and these are detailed in Table 1.…”

Section: Aimmentioning

confidence: 99%

“…A method of measuring CIs on a slice-by-slice basis may be more informative. At the time of writing, there are tools available to calculate both JCI/GMI/DI (local conformity) [20] and the MDC on a slice-by-slice basis (axial conformity), and these tools have been applied to the SCOPE 1 [40], SCALOP (SM, unpublished work, Northampton General Hospital, 2011-12) and ARISTOTLE accrual benchmark cases [42].…”

Section: Aimmentioning

confidence: 99%

See 1 more Smart Citation

Improving radiotherapy quality assurance in clinical trials: assessment of target volume delineation of the pre-accrual benchmark case

Gwynne¹,

Spezi²,

Sebag‐Montefiore³

et al. 2013

BJR

View full text Add to dashboard Cite

As the complexity of radiotherapy (RT) trials increases, issues surrounding target volume delineation will become more important. Some form of outlining assessment prior to trial entry is increasingly being mandated in UK RT trials. This document produced by the Outlining and Imaging Subgroup (OISG) of the National Cancer Research Institute will address methods to reduce interobserver variation in clinical trials and how to conduct an assessment of outlining through a pre-accrual benchmark case. We review currently available methods of describing the variation and identify areas where further work is needed. The OISG would encourage ongoing discussion with chief investigators in order to provide advice on individual aspects of benchmark case assessment for current and future trials.The importance of quality assurance (QA) in radiotherapy (RT) trials has been highlighted by recent publications showing that protocol deviations can negatively impact on survival in head and neck and pancreatic cancer trials [1,2]. These studies have focused predominantly on planning rather

show abstract